Enterprise Value
10.17M
Cash
21.61M
Avg Qtr Burn
-3.044M
Short % of Float
2.53%
Insider Ownership
11.67%
Institutional Own.
17.70%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATRN-119 Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
APR-1051 Details Solid tumor/s, Cancer | Phase 1 Initiation | |
Eprenetapopt (APR-246) + azacitidine Details Acute myeloid leukemia, Cancer, Myelodysplastic syndrome | Failed Discontinued | |
Eprenetapopt (APR-246) + Azacitidine Details Blood disorder, Myelodysplastic syndrome | Failed Discontinued | |
APR-548 + azacitidine Details Mutant Myelodysplastic Syndromes | Failed Discontinued |